Case | sCr mg/dL (EPI-GFR mL/min) | Stage CKD | PtU g/24 h | Pt/Alb (g/dL) | Weight gain (Kg) | sCr mg/dL (EPI-GFR mL/min) 3 months | PtU g/die Serum Alb g/dl 3 months |
---|---|---|---|---|---|---|---|
1 | 0.9 (85) | 2 | 1.5 | 5.3/2.9 | 10 | 0.9 (85) | 1.7/3.7 |
2 | 0.8 (96) | 1 | 7.2 | 6.9/3.3 | 10 | 0.8 (96) | 0.8/4 |
3 | 0.7 (113) | 1 | 8.8 | 6.3/3.1 | 10 | 0.8 (96) | 0.4/3.8 |
4 | 0.8 (94) | 1 | 1.5 | na | na | na | na |
5 | 0.9 (86) | 2 | 1.1 | 5.7/2.9 | 15 | 1 (76) | 1.3/ 3.7 |
6 | 0.5 (136) | 1 | 0.8 | 5.9/2.9 | 14 | 0.5 (129) | 0.4/4.3 |
7 | 0.5 (124) | 1 | 4.0 | 5.4/2.5 | 14 | 0.5 (125) | 1.4/3.2 |
8 | 0.5 (141) | 1 | 3.7 | 5.7/ 3.0 | 10 | 0.6 (130) | 3.1/4.3 |
9 | 1.0 (72) | 2 | 6.2 | 5.1/2.8 | 18 | 1.1 (64) | 3.5/ 3.7 |
10 | 1.3 (51) | 3 | 7.9 | 4.7/2 | 12 | 1.3 (51) | 1.3/ 3.1 |
11 | 2.3 (27) | 4 | 8.3 | na | na | na | na |
12 | 1.4 (47) | 3 | 2.5 | 6/3.3 | 14 | 1.5 (43) | 2.1/na |
13 | 1.4 (50) | 3 | 6.3 | 5.2/3.1 | 13 | 1.4 (49) | 1/4.1 |
14 | 1.4 (48) | 3 | 3.6 | 6.4/3.0 | 18 | 1.5 (44) | 3.2/na |
15 | 1.8 (35) | 3 | 4.4 | 5.6/2.8 | 11 | 1.9 (33) | 5.7/3.3 |
16 | 1.6 (42) | 3 | 1.8 | 6.1/3.0 | 8 | 1.3 (55) | 2.4/3.9 |
17 | 1.7 (38) | 3 | 5.6 | 5.9/2.9 | 9 | 1.8 (35) | 5.7/3.6 |
18 | 1.7 (42) | 3 | 5.6 | 6.2/3.3 | 7 | 1.9 (36) | 8/4 |
19 | 1.4 (50) | 3 | 6.2 | 5.3/3.3 | 8 | 0.9 (131) | 1.6/4.1 |
20 | 2.0 (32) | 3 | 5.1 | 5.7/3.2 | 4 | 1.8 (37) | 5.4/3 |
21 | 2.3 (27.8) | 4 | 7.1 | 6.8/3.1 | 10 | 2.4 (26) | 2.7/4.2 |
22 | 0.5 (127) | 1 | 0.5 | 7.5/3.8 | 17 | 0.7 (114) | 0.8/4.6 |
Summary data (Cagliari) | sCr 1.35 (0.5–2.3) GFR-EPI 50.5 (27.0–141.0) | 3 (1–4) | 4.75 (0.5–8.8) | Pt 5.8 (4.7–7.5) Alb 3.0 (2.0–3.8) | 10.5 (4–18) | sCr 1.20 (0.5–2.4) GFR-EPI 59.5 (26.0–131.0) | PtU 1.90 (0.4–8.0) Serum Alb 3.85 (3.0–4.6) |
1 | 0.83 (121) | 1 | 1.08 | 6.1/3.8 | 8 | 1.2 (57) | 1.0/3.5 |
2 | 0.69 (80.5) | 2 | 1.61 | 6.1/2.9 | 12 | 1.4 (66) | 0.9/3.7 |
3 | 1.06 (86) | 2 | 2.83 | 6.343.3 | 10 | 1.7 (39) | 1.2/ns |
4 | 0.59 (112) | 1 | 0.1 | 7.01/3.58 | 8 | 1.9 (42) | 2.5/3.2 |
5 | 0.83 (121) | 1 | 1.08 | 6.08/3.80 | 8 | 1.2 (52) | 0.8/3.7 |
6 | 0.69 (80.5) | 2 | 1.61 | 6.11/2.95 | 10 | Na | na |
7 | 1.06 (86) | 2 | 2.83 | 6.34/3.28 | 2 | 5.2 (11) | na |
8 | 0.59 (112) | 1 | 0.1 | 7.01/3.58 | 6 | 2.1 (29) | 0.5/4.0 |
9 | 0.83 (121) | 1 | 1.08 | 6.08/3.80 | 11 | 2.2 (29) | 1.2/3.7 |
10 | 0.69 (80.5) | 2 | 1.61 | 6.11/2.95 | 19 | 1.3 (57) | 0.7/4.1 |
11 | 1.06 (86) | 2 | 2.83 | 6.34/3.28 | 11 | 1.1 (62) | 0.1/4.1 |
12 | 0.59 (112) | 1 | 0.1 | 7.01/3.58 | 15 | 1.5 (45) | 0.2/3.7 |
13 | 0.83 (121) | 1 | 1.08 | 6.08/3.8 | 14 | 0.9 (85) | 0.3/3.8 |
14 | 0.69 (80.5) | 2 | 1.61 | 6.11/2.95 | 7 | 1.2 (72) | na |
15 | 1.06 (86) | 2 | 2.83 | 6.34/3.28 | 3 | na | na |
16 | 0.59 (112) | 1 | 0.1 | 7.01/3.58 | 13 | 0.9 (55a) | 0.1/4.2 |
17 | 0.83 (121) | 1 | 1.08 | 6.08/3.80 | 14 | na | na |
18 | 0.69 (80.5) | 2 | 1.61 | 6.11/2.95 | 3 | na | na |
19 | 1.06 (86) | 2 | 2.83 | 6.34/3.28 | 2 | na | na |
20 | 0.59 (112) | 1 | 0.1 | 7.01/3.58 | 19 | na | na |
Summary data Torino | sCr 0.76 (0.59–1,06) GFR-EPI 99.0 (80.5–121.0) | 1.34 (0.1–2.83) | Pt 6.2 (6.08–7.01) Alb 3.44 (2.9–3.8) | 10.0 (2–19) | sCr 1.35 (0.9–5.2) GFR-EPI 53.5 (11.0–85.0) | PtU 0.75 (0.1–2.5) Serum Alb 3.7 (3.2–4.2) | |
Summary data, all | sCr 0.83 (0.5–2.3) GFR-EPI 86.0 (27.0–141.0) | 2.15 (0.1–8.8) | Pt 6.1 (4.7–7.5) Alb 3.24 (2.0–3.8) | 10.0 (2–19) | sCr 1.3 (0.5–5.2) GFR-EPI 55.0 (11.0–131.0) | PtU 1.25 (0.1–8.0) Serum Alb 3.8 (3.0–4.6) | |
P controls vs on diet | sCr 0.018 GFR-EPI 0.018 | 0.390 (Chi2) | 0.876 | 0.010 | 0.364 | sCr 0.565 GFR-EPI 0.813 | PtU 0.499 Serum Alb 0.074 |